Skip to main content

Proteome Sciences, Sigma-Aldrich Reach Deal to Sell ProteoPrep Products


Proteome Sciences this week entered into a non-exclusive licensing deal allowing Sigma-Aldrich to continue selling products under the ProteoPrep name in Europe, Japan, and Australia.

Sigma-Aldrich has been selling immunodepletion kits under ProteoPrep name, which is a trademark registered to Proteome Sciences in the three geographies covered by this week's announcement.

Currently, Sigma-Aldrich sells 11 ProteoPrep kits. The license includes those products and all future products containing chemicals and reagents for disrupting cells, tissues, or other biological material, and the extraction of biological molecules such as proteins, lipids, and carbohydrates.

The deal also covers methods and processes related to assays for diagnosing disease, as well as chemical markers for determining proteins and peptides by disruption of cells, tissues, and other biological materials, and for targeting drugs.

Proteome Sciences received a signing fee and will receive royalties on product sales. Other financial terms of the deal were not disclosed.

The Scan

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.